Literature DB >> 23493783

Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.

Jaap Jan Boelens1, Mieke Aldenhoven, Duncan Purtill, Annalisa Ruggeri, Todd Defor, Robert Wynn, Ed Wraith, Marina Cavazzana-Calvo, Attilio Rovelli, Alain Fischer, Jakub Tolar, Vinod K Prasad, Maria Escolar, Eliane Gluckman, Anne O'Meara, Paul J Orchard, Paul Veys, Mary Eapen, Joanne Kurtzberg, Vanderson Rocha.   

Abstract

We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The cumulative incidence of neutrophil recovery at day 60 was 91%, acute graft-versus-host disease (GVHD) (grade II-IV) at day 100 was 25%, and chronic GVHD and 5 years was 16%. Overall survival and event-free survival (EFS) at 5 years were 74% and 63%, respectively. EFS after HLA-matched sibling donor (MSD) and 6/6 matched unrelated cord blood (CB) donor were similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matched CB donor. EFS was lower after transplantation in 4/6 matched unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007). Full-donor chimerism (P = .039) and normal enzyme levels (P = .007) were higher after CB transplantation (92% and 98%, respectively) compared with the other grafts sources (69% and 59%, respectively). In conclusion, results of allogeneic transplantation for HS are encouraging, with similar EFS rates after MSD, 6/6 matched UCB, 5/6 UCB, and 10/10 matched UD. The use of mismatched UD and 4/6 matched UCB was associated with lower EFS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23493783      PMCID: PMC3836041          DOI: 10.1182/blood-2012-09-455238

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts.

Authors:  J C Fratantoni; C W Hall; E F Neufeld
Journal:  Science       Date:  1968-11-01       Impact factor: 47.728

Review 3.  The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.

Authors:  James Edward Wraith
Journal:  Expert Opin Pharmacother       Date:  2005-03       Impact factor: 3.889

4.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

5.  Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group.

Authors:  C Peters; E G Shapiro; J Anderson; P J Henslee-Downey; M R Klemperer; M J Cowan; E F Saunders; P A deAlarcon; C Twist; J B Nachman; G A Hale; R E Harris; M K Rozans; J Kurtzberg; G H Grayson; T E Williams; C Lenarsky; J E Wagner; W Krivit
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

6.  Enzyme-replacement therapy in mucopolysaccharidosis I.

Authors:  E D Kakkis; J Muenzer; G E Tiller; L Waber; J Belmont; M Passage; B Izykowski; J Phillips; R Doroshow; I Walot; R Hoft; E F Neufeld
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

7.  Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation.

Authors:  J R Hobbs; K Hugh-Jones; A J Barrett; N Byrom; D Chambers; K Henry; D C James; C F Lucas; T R Rogers; P F Benson; L R Tansley; A D Patrick; J Mossman; E P Young
Journal:  Lancet       Date:  1981-10-03       Impact factor: 79.321

8.  Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.

Authors:  Susan L Staba; Maria L Escolar; Michele Poe; Young Kim; Paul L Martin; Paul Szabolcs; June Allison-Thacker; Susan Wood; David A Wenger; Pablo Rubinstein; John J Hopwood; William Krivit; Joanne Kurtzberg
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

9.  Follow-up of nine patients with Hurler syndrome after bone marrow transplantation.

Authors:  N Guffon; G Souillet; I Maire; J Straczek; P Guibaud
Journal:  J Pediatr       Date:  1998-07       Impact factor: 4.406

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  64 in total

1.  Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Authors:  Radojka M Savic; Morton J Cowan; Christopher C Dvorak; Sung-Yun Pai; Luis Pereira; Imke H Bartelink; Jaap J Boelens; Robbert G M Bredius; Rob F Wynn; Geoff D E Cuvelier; Peter J Shaw; Mary A Slatter; Janel Long-Boyle
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-09       Impact factor: 5.742

Review 2.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 3.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

Review 4.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

Review 5.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 6.  Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.

Authors:  Shalini Shenoy; Jaap J Boelens
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

Review 7.  Umbilical cord blood donation: public or private?

Authors:  K K Ballen; F Verter; J Kurtzberg
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

8.  New Insights Into Multicenter PICU Mortality Among Pediatric Hematopoietic Stem Cell Transplant Patients.

Authors:  Matt S Zinter; Christopher C Dvorak; Aaron Spicer; Morton J Cowan; Anil Sapru
Journal:  Crit Care Med       Date:  2015-09       Impact factor: 7.598

Review 9.  The transformative potential of HSC gene therapy as a genetic medicine.

Authors:  Pervinder Sagoo; H Bobby Gaspar
Journal:  Gene Ther       Date:  2021-05-26       Impact factor: 5.250

10.  The increase of the global donor inventory is of limited benefit to patients of non-Northwestern European descent.

Authors:  Suzanna M van Walraven; Anneke Brand; Jack N A Bakker; Martin B A Heemskerk; Suzan Nillesen; Marc B Bierings; Laura B Bungener; Bouke G Hepkema; Arjan Lankester; Arnold van der Meer; Kees Sintnicolaas; Judith A E Somers; Eric Spierings; Marcel G J Tilanus; Christien E M Voorter; Jan J Cornelissen; Machteld Oudshoorn
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.